INPHARMD · FORMULARY IQ

The Right Drug.
Clinically Driven.
Financially Optimized.

Formulary IQ synthesizes your drug acquisition cost, utilization patterns, patient specific reimbursement, and clinical evidence to recommend the right medication at the right site of care, across inpatient and outpatient settings.

LIVE IMPACT
Q1 2026 · 22 ACTIVE SITES
TOTAL FINANCIAL OPPORTUNITY
$856,033
Across 10 drug groups, 9 with opportunity.
HIGHEST OPPORTUNITY
Bevacizumab
$250,035
On $346,320 annual 340B spend.
HIGHEST MARGIN GAIN
Pegfilgrastim
+$253,002
Q4 2025 → Q1 2026 · +$48.77/unit (+58%).
TRUSTED BY LEADING HEALTH SYSTEMS

/ The problem

Four forces are reshaping pharmacy decisions simultaneously.

No team can keep pace with all of them by hand. InpharmD watches every signal, every day, across every drug class.

Expanding therapy landscape

New drugs, new indications, and new generic and biosimilar entrants launch every quarter, each with its own evidence and economics.

Evolving clinical evidence

Guidelines, label updates, and head-to-head trial data are revised constantly. What was first-line last quarter may not be today.

Shifting payer reimbursement

Step-therapy rules, prior-auth criteria, and contract terms change throughout the year across hundreds of plans.

Volatile drug pricing

WAC, ASP, 340B, and rebate dynamics swing margin per encounter, often without notice.

/ The solution

Choose the right therapy. Maximize financial performance.

01 — OPTIMAL THERAPY SELECTION

Find the best fit for every patient.

Identify the financially preferred, clinically supported therapy in seconds.

02 — REAL PLAYER COVERAGE

Know what's covered-instantly.

Covered products and viable therapies surface from real payer data, so teams acton coverage reality, not assumptions

03 — PERFORMANCE ANALYTICS

Measure performance from every angle.

A fast, flexible way to measure overall performance.

04 — FORMULARY MODELING AND ANALYSIS

Model formulary decisions before you commit.

Run full financial analysis on any formulary change built on your actual cost,reimbursement and utilization data.

INPATIENT THERAPEUTIC INTERCHANGE

Cut inpatient drug expense.

Inpatient interchange recommendations built on your cost and utilization data, informed by decisions across InpharmD's network of health systems.